Hi synaphai, you said “So I think our large upcoming US pivotal trial will likely will serve both a US and Canada approval”. My post was more towards ViV, and I am thinking if a separate ViV study in Canada may bring to a quicker commercialisation approval of DurAVR in Canada. I recalled you might have mentioned a separate ViV trial maybe needed for FDA clearance?
Not advice and DYOR
Ann: Three ViV Patients Completed under Health Canada SAP, page-25
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.56 |
Change
-0.740(5.56%) |
Mkt cap ! $265.4M | |||
| Open | High | Low | Value | Volume |
| $13.06 | $13.30 | $12.55 | $359.0K | 27.63K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 399 | $12.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.78 | 500 | 1 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| AVR (ASX) Chart |